PANACEABIOPharmaceuticals
Panacea Biotec Ltd — Profit & Loss Statement
₹296.05
-2.65%
Panacea Biotec Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 10.80 Cr | 10.81 Cr | 31.62 Cr | 428.69 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.30 | 0.30 | 0.26 | — |
| Normalized EBITDA | -5.25 Cr | 5.74 Cr | -49.68 Cr | -1.67 Cr | — |
| Total Unusual Items | 35.99 Cr | 36.03 Cr | 105.41 Cr | 1.67K Cr | — |
| Total Unusual Items Excluding Goodwill | 35.99 Cr | 36.03 Cr | 105.41 Cr | 1.67K Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -8.37 Cr | -1.17 Cr | -33.24 Cr | 1.08K Cr | — |
| Reconciled Depreciation | 34.81 Cr | 36.71 Cr | 39.12 Cr | 43.78 Cr | — |
| Reconciled Cost Of Revenue | 199.54 Cr | 230.12 Cr | 278.76 Cr | 317.67 Cr | — |
| EBITDA | 30.74 Cr | 41.77 Cr | 55.73 Cr | 1.67K Cr | — |
| EBIT | -4.07 Cr | 5.06 Cr | 16.61 Cr | 1.63K Cr | — |
| Net Interest Income | -3.88 Cr | -3.58 Cr | 7.12 Cr | -177.44 Cr | — |
| Interest Expense | 3.88 Cr | 3.58 Cr | 3.80 Cr | 179.84 Cr | — |
| Normalized Income | -33.56 Cr | -26.39 Cr | -107.03 Cr | -167.63 Cr | — |
| Net Income From Continuing And Discontinued Operation | -8.37 Cr | -1.17 Cr | -33.24 Cr | 1.08K Cr | — |
| Total Expenses | 619.81 Cr | 615.94 Cr | 562.57 Cr | 711.04 Cr | — |
| Diluted Average Shares | 6.11 Cr | 6.16 Cr | 6.13 Cr | 6.13 Cr | — |
| Basic Average Shares | 6.11 Cr | 6.16 Cr | 6.13 Cr | 6.13 Cr | — |
| Diluted EPS | -1.37 | -0.19 | -5.43 | 176.05 | — |
| Basic EPS | -1.37 | -0.19 | -5.43 | 176.05 | — |
| Diluted NI Availto Com Stockholders | -8.37 Cr | -1.17 Cr | -33.24 Cr | 1.08K Cr | — |
| Net Income Common Stockholders | -8.37 Cr | -1.17 Cr | -33.24 Cr | 1.08K Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -8.37 Cr | -1.17 Cr | -33.24 Cr | 1.08K Cr | — |
| Minority Interests | 0.35 Cr | 0.33 Cr | 0.51 Cr | -0.02 Cr | — |
| Net Income Including Noncontrolling Interests | -8.72 Cr | -1.50 Cr | -33.74 Cr | 1.08K Cr | — |
| Net Income Continuous Operations | -8.72 Cr | -1.50 Cr | -33.74 Cr | 1.08K Cr | — |
| Tax Provision | 0.77 Cr | 2.98 Cr | 46.55 Cr | 371.02 Cr | — |
| Pretax Income | -7.95 Cr | 1.48 Cr | 12.80 Cr | 1.45K Cr | — |
| Other Non Operating Income Expenses | 20.66 Cr | 25.80 Cr | 3.34 Cr | 3.40 Cr | — |
| Special Income Charges | 35.99 Cr | 36.03 Cr | 103.97 Cr | 1.67K Cr | — |
| Other Special Charges | -35.99 Cr | -36.03 Cr | -107.39 Cr | -1.68K Cr | — |
| Net Non Operating Interest Income Expense | -3.88 Cr | -3.58 Cr | 7.12 Cr | -177.44 Cr | — |
| Interest Expense Non Operating | 3.88 Cr | 3.58 Cr | 3.80 Cr | 179.84 Cr | — |
| Operating Income | -60.72 Cr | -56.77 Cr | -105.65 Cr | -51.81 Cr | — |
| Operating Expense | 420.27 Cr | 385.82 Cr | 283.81 Cr | 393.37 Cr | — |
| Other Operating Expenses | 212.41 Cr | 199.54 Cr | 58.43 Cr | 87.98 Cr | — |
| Depreciation And Amortization In Income Statement | 34.81 Cr | 36.71 Cr | 39.12 Cr | 43.78 Cr | — |
| Depreciation Income Statement | 34.81 Cr | 36.71 Cr | 38.85 Cr | 43.02 Cr | — |
| Gross Profit | 359.55 Cr | 329.05 Cr | 178.16 Cr | 341.56 Cr | — |
| Cost Of Revenue | 199.54 Cr | 230.12 Cr | 278.76 Cr | 317.67 Cr | — |
| Total Revenue | 559.09 Cr | 559.17 Cr | 456.92 Cr | 659.22 Cr | — |
| Operating Revenue | 559.09 Cr | 559.17 Cr | 456.92 Cr | 659.22 Cr | — |
| Interest Income | — | 8.37 Cr | 11.56 Cr | 3.39 Cr | 3.27 Cr |
| Rent Expense Supplemental | — | 3.40 Cr | 3.44 Cr | 3.40 Cr | 2.87 Cr |
| Write Off | — | 0.54 Cr | 0.43 Cr | 0.00 | 0.00 |
| Impairment Of Capital Assets | — | 4.61 Cr | 2.99 Cr | 1.57 Cr | 0.27 Cr |
| Total Other Finance Cost | — | 0.91 Cr | 0.63 Cr | 1.00 Cr | 0.65 Cr |
| Interest Income Non Operating | — | 8.37 Cr | 11.56 Cr | 3.39 Cr | 3.27 Cr |
| Amortization | — | 2.35 Cr | 0.28 Cr | 0.76 Cr | 0.83 Cr |
| Selling General And Administration | — | 58.05 Cr | 58.55 Cr | 75.75 Cr | 78.65 Cr |
| Selling And Marketing Expense | — | 28.52 Cr | 42.70 Cr | 48.08 Cr | 51.18 Cr |
| General And Administrative Expense | — | 29.53 Cr | 15.84 Cr | 27.67 Cr | 27.47 Cr |
| Rent And Landing Fees | — | 3.40 Cr | 3.44 Cr | 3.40 Cr | 2.87 Cr |
| Net Income Discontinuous Operations | — | — | — | 0.00 | -1.46 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Panacea Biotec Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.